Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Jan 24, 2013 12:43pm
210 Views
Post# 20884928

RE: Alamos deal reject

RE: Alamos deal reject

It's anyone's guess what will happen as we're on the outside looking in.  There is clearly some (not a lot but some) selling related to the latest Alamos/Aurizon development.  Bottom line is fundamentals at NOX remain unchanged.

Yes, you've held for 2 years but juniors (especially junior explorers) haven't fared well during this time period.  They're still in a bear market although gold has held up, and eventually fundamentals will be recognized.  When that will happen, no-one knows.

Hindsight is always 20/20 and it would have been nice to take a 50% gain on the stock and buy back at a low price.  However, I don't think a lot of people are trading this stock - it's a long-term holding that should return multiples on the investment.  We're all to some degree frustrated but the fundamentals are in place and I believe NOX has a management team that can execute and the treasury to avoid any significant dilution.

 

MM

<< Previous
Bullboard Posts
Next >>